Clinical Positioning and Future Prospects of JAK Inhibitors in Alopecia Areata

March 2026 in “ Expert Opinion on Pharmacotherapy ”

M. Wada-Irimada, Takehiro Takahashi, Y. Asano

JAK inhibitors alopecia areata autoimmune disease non-scarring hair loss biomarkers clinical trials real-world studies early intervention standardized monitoring treatment continuation dose adjustments combination therapies Janus kinase inhibitors AA

TLDR JAK inhibitors are effective for severe alopecia areata but need better strategies for long-term use and personalized treatment.

The document discusses the clinical positioning and future prospects of Janus kinase (JAK) inhibitors in the treatment of alopecia areata. JAK inhibitors have shown promise in managing this autoimmune condition, which causes hair loss, by targeting specific pathways involved in the immune response. The authors highlight the potential of these inhibitors to provide effective treatment options for patients with alopecia areata, emphasizing the need for further research to optimize their use and understand long-term effects. The study underscores the importance of personalized medicine approaches in improving outcomes for individuals affected by this condition.

View this study on doi.org →

Discuss this study in the Community →

Research cited in this study

49 / 49 results

research Ritlecitinib in Alopecia Areata: A 24-Week Real-World Experience Contrasting JAK Inhibitor-Naïve and JAK Inhibitor-Experienced Patients

December 2025 in “The Journal of Dermatology”

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

research Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy

July 2025 in “Allergy”

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

research Long-Term Real-World Outcomes of Baricitinib in Severe Alopecia Areata: A 104-Week Retrospective Analysis From a Single Institute

June 2025 in “The Journal of Dermatology”

Baricitinib is effective and safe for long-term treatment of severe alopecia areata.

research Single-Cell Analysis of Temporal Immune Cell Dynamics in Alopecia Areata Reveals a Causal Role for Clonally Expanded CD8+ T Cells in Disease

4 citations , June 2025 in “Cell Reports”

Clonally expanded CD8+ T cells cause alopecia areata.

research Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib

April 2025 in “PubMed”

Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.

research Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme

13 citations , February 2025 in “Journal of the European Academy of Dermatology and Venereology”

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center

research Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center

January 2025 in “The Journal of Dermatology”

Certain patient traits can predict better hair regrowth with baricitinib in severe alopecia areata.

research Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study

15 citations , January 2025 in “Journal of the European Academy of Dermatology and Venereology”

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

research Hidradenitis Suppurativa Tunnels: Unveiling a Unique Disease Entity

3 citations , January 2025 in “JID Innovations”

Hidradenitis suppurativa tunnels worsen the disease and often need surgery because current treatments are not very effective.

research Clinical Efficacy and Safety of Baricitinib in Patients With Alopecia Areata in Korea

1 citations , January 2025 in “Annals of Dermatology”

Baricitinib is effective and safe for treating alopecia areata in Korea.

Continued Treatment With Baricitinib Results in Meaningful Scalp Responses Among Scalp Non-Responder Patients With Eyebrow/Eyelash Regrowth in the First Year

research Continued Treatment With Baricitinib Results in Meaningful Scalp Responses Among Scalp Non-Responder Patients With Eyebrow/Eyelash Regrowth in the First Year

November 2024 in “Journal of the European Academy of Dermatology and Venereology”

Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.

research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata

August 2024 in “JAMA Dermatology”

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

research Alopecia Areata Exhibits Cutaneous And Systemic OX40 Activation Across Atopic Backgrounds

August 2024 in “Allergy”

Alopecia areata patients show increased inflammation and OX40 activation, suggesting a new treatment target.

research Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1)

63 citations , July 2024 in “Journal of the American Academy of Dermatology”

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

research Real-World Effectiveness and Safety of Tofacitinib for Alopecia Areata: A Retrospective Cohort Study of 202 Patients

June 2024 in “Australasian Journal of Dermatology”

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2

February 2024 in “Journal of the European Academy of Dermatology and Venereology”

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

January 2024 in “American journal of clinical dermatology”

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

research Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients

January 2024 in “Acta dermato-venereologica”

Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

September 2023 in “British Journal of Dermatology”

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

research Combination of Baricitinib and Conventional Immunomodulating Therapy for Alopecia Totalis

July 2023 in “Skin Research and Technology”

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

research Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial

48 citations , July 2023 in “Pediatric Dermatology”

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

research Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population

75 citations , March 2023 in “JAMA Dermatology”

Alopecia areata and its severe forms are becoming more common, especially among females, adults, and people in the Northeast.

research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials

20 citations , March 2023 in “American Journal of Clinical Dermatology”

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

research Prevalence, Comorbidities, and Treatment Patterns of Japanese Patients with Alopecia Areata: A Descriptive Study Using Japan Medical Data Center Claims Database

35 citations , November 2022 in “The Journal of Dermatology”

Alopecia areata is becoming more common in Japan, with a need for better treatments, especially for severe and pediatric cases.

research Sisaipho Alopecia Areata Treated With Tofacitinib and Oral Minoxidil

1 citations , August 2022 in “JAAD case reports”

Tofacitinib and oral minoxidil may help treat Sisaipho alopecia areata.

research Whole Exome Sequencing in Alopecia Areata Identifies Rare Variants in KRT82

9 citations , February 2022 in “Nature communications”

Rare changes in the KRT82 gene are linked to a higher risk of Alopecia Areata.

research Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial

20 citations , December 2021 in “Journal of the American Academy of Dermatology”

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

research Clinical Response to Adjunctive Platelet-Rich Plasma Injections in a Patient with Alopecia Universalis on Oral Tofacitinib

1 citations , December 2021 in “JAAD case reports”

A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.

research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata

42 citations , April 2021 in “JCI insight”

Blocking JAK3 signaling can reverse hair loss from alopecia areata.

research Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata

134 citations , July 2020 in “Experimental dermatology”

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

research Alopecia Areata Susceptibility Variant in MHC Region Impacts Expressions of Genes Contributing to Hair Keratinization and Is Involved in Hair Loss

19 citations , July 2020 in “EBioMedicine”

A gene variant increases the risk of a type of hair loss by affecting hair protein production.

research Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata

37 citations , January 2019 in “JAMA Dermatology”

People with Major Depressive Disorder have a higher chance of getting Alopecia Areata, and vice versa; antidepressants may lower this risk.

research High-Throughput T Cell Receptor Sequencing Identifies Clonally Expanded CD8+ T Cell Populations in Alopecia Areata

46 citations , October 2018 in “JCI insight”

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

research Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing

176 citations , August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

research Epidemiology and Burden of Alopecia Areata: A Systematic Review

144 citations , July 2015 in “Clinical, Cosmetic and Investigational Dermatology”

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

184 citations , February 2015 in “EBioMedicine”

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

research Inhibiting Janus Kinases to Treat Alopecia Areata

52 citations , September 2014 in “Nature medicine”

JAK inhibitors might help treat alopecia areata.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

185 citations , June 2014 in “Journal of Investigative Dermatology”

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

research Multivariate Analysis of Prognostic Factors in Patients With Rapidly Progressive Alopecia Areata

26 citations , September 2012 in “Journal of The American Academy of Dermatology”

Patients with rapidly progressive alopecia areata often have a better outlook and shorter disease duration, with regrown fine hairs and no past alopecia being positive signs.

research Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity

717 citations , June 2010 in “Nature”

Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.

research Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack

253 citations , December 2007 in “Journal of Investigative Dermatology”

Hair follicles prevent NK cell attacks to avoid hair loss.

research Major Histocompatibility Complex Class I Chain-Related Gene A Polymorphisms and Extended Haplotypes Are Associated with Familial Alopecia Areata

44 citations , December 2005 in “Journal of Investigative Dermatology”

Certain genetic markers, especially the MICA gene, are linked to alopecia areata.

research Alopecia Areata: A Tissue-Specific Autoimmune Disease of the Hair Follicle

185 citations , August 2005 in “Autoimmunity Reviews”

Alopecia areata is an autoimmune condition causing hair loss due to the immune system attacking hair follicles, often influenced by genetics and stress.

research Acute Diffuse and Total Alopecia of the Female Scalp

59 citations , January 2002 in “Dermatology”

A new type of sudden, complete female hair loss was found, with most patients fully recovering within 6 months without needing steroid treatment.